• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BiomX Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/15/25 8:01:09 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    false 0001739174 0001739174 2025-05-15 2025-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    Form 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 15, 2025

     

    BiomX Inc.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-38762   82-3364020
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    22 Einstein St., Floor 4

    Ness Ziona, Israel

      7414003
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: +972 723942377

     

    n/a
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   PHGE   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 15, 2025, BiomX Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release issued in connection with the announcement is furnished pursuant to this Item 2.02 as Exhibit 99.1 hereto.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit   Description
    99.1   Press Release dated May 15, 2025 (furnished herewith)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL documents)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BIOMX INC.
         
    May 15, 2025 By: /s/ Jonathan Solomon
        Name:  Jonathan Solomon
        Title: Chief Executive Officer

     

     

    2

     

    Get the next $PHGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

      NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will present at the Biomed Israel 2025 conference, reviewing the Company's topline Phase 2 results for BX211 in DFO. The conference is being held between May 20 - 22, 2025, in Tel Aviv, Israel. Presentation Details Oral Presentation TitlePrecision Phage Therapy for Chronic Diabetic Foot Infections  SessionImmunology & Inflammation; Reclaim Top Priorities in BioPharma: Driver and Opportunities?  Session T

      5/19/25 10:02:04 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

      In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast today at 2:00 PM ET NESS ZIONA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage ther

      5/15/25 6:30:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by *Director by Deputization Flynn James E

      4 - BiomX Inc. (0001739174) (Issuer)

      4/23/25 5:49:02 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 4 filed by Director Merril Gregory Louis

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:24:29 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Development Officer Bassan Merav was granted 79,597 shares (SEC Form 4)

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:11:31 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

      11/16/21 9:23:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

      10/19/21 8:36:54 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on BiomX with a new price target

      HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

      10/18/21 12:27:44 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    See more
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Telum Therapeutics appoints Dr. Subhendu Basu as CEO

      Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

      3/19/24 5:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

      10/18/23 8:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/13/24 5:14:46 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/4/24 4:05:35 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      10/28/24 4:01:32 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by BiomX Inc.

      SCHEDULE 13G/A - BiomX Inc. (0001739174) (Subject)

      5/15/25 4:39:25 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by BiomX Inc.

      SCHEDULE 13G - BiomX Inc. (0001739174) (Subject)

      5/15/25 4:29:04 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by BiomX Inc.

      10-Q - BiomX Inc. (0001739174) (Filer)

      5/15/25 4:01:50 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Financials

    Live finance-specific insights

    See more
    • BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

      In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast today at 2:00 PM ET NESS ZIONA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage ther

      5/15/25 6:30:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

      BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

      3/31/25 6:30:57 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care